Brief: Idera Pharmaceuticals Completes Enrollment In Illuminate-301, Its Registrational Trial Of Tilsotolimod In Combination With Ipilimumab In Patients With Anti-Pd-1 Refractory Advanced Melanoma

Aceragen

05/03/2020 12:17

March 5 (Reuters) - Idera Pharmaceuticals Inc  IDRA.O :
    * IDERA PHARMACEUTICALS COMPLETES ENROLLMENT IN
ILLUMINATE-301,
ITS REGISTRATIONAL TRIAL OF TILSOTOLIMOD IN COMBINATION WITH
IPILIMUMAB IN PATIENTS WITH ANTI-PD-1 REFRACTORY ADVANCED
MELANOMA
    * IDERA PHARMA- EXPECTS TOP-LINE OVERALL RESPONSE RATE AND
OTHER
PRELIMINARY DATA FROM ILLUMINATE-301 IN Q1 2021

Source text for Eikon:  ID:nGNX5368Mh 
Further company coverage:  IDRA.O 

 ((Reuters.Briefs@thomsonreuters.com;))